Skip to content

Endocrine · Reference monograph

Active fragment of parathyroid hormone with anabolic bone activity

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Teriparatide is recombinant human parathyroid hormone fragment 1-34, the N-terminal sequence of the 84-amino-acid hormone that contains the activity required for receptor activation. It was developed by Eli Lilly and approved by the FDA in 2002, becoming the first bone-building, or osteoanabolic, agent for osteoporosis. It is an approved prescription medicine for osteoporosis in people at high fracture risk, and biosimilar versions are now available in several markets.

Teriparatide is central to one of bone biology's most important paradoxes. Continuous elevation of parathyroid hormone, as in hyperparathyroidism, promotes bone resorption, yet intermittent exposure stimulates bone formation more than resorption, producing net bone gain. The Fracture Prevention Trial, published in 2001, established the clinical relevance of this concept. Early rodent carcinogenicity studies found osteosarcoma in rats given long-term high exposure, leading to a boxed warning in the US that was later removed. Researchers use teriparatide to study bone anabolism, PTH1 receptor signalling, osteoblast lineage biology and fracture outcomes.

Mechanism studied

  1. Teriparatide
  2. PTH1 receptor
  3. Osteoblast activation
  4. Bone formation

Teriparatide activates the parathyroid hormone 1 receptor (PTH1R), a class B G protein-coupled receptor expressed on osteoblasts, osteocytes and renal tubular cells. PTH1R couples to Gs-cAMP-protein kinase A and to Gq-phospholipase C signalling. In bone, intermittent activation increases osteoblast number and activity by stimulating differentiation of precursors, reactivating quiescent lining cells and reducing osteoblast apoptosis. It also suppresses osteocyte expression of sclerostin, an inhibitor of Wnt signalling, and influences RANKL and osteoprotegerin expression. The early dominance of formation over resorption markers is often called the anabolic window. In the kidney, PTH1R activation enhances calcium reabsorption and phosphate excretion.

Research highlights

  • 01Approved by the FDA in 2002 as the first osteoanabolic agent for osteoporosis.
  • 02The intermittent-versus-continuous PTH paradox remains a foundational concept in skeletal biology.
  • 03Rat osteosarcoma findings shaped regulatory history; the US boxed warning was removed in 2020.
  • 04The Fracture Prevention Trial and later comparative studies made teriparatide a reference arm in bone research.
  • 05Open questions include how signalling duration at PTH1R determines anabolic versus catabolic outcomes.

Latest published research

4,478 papers on PubMed →

  1. Bone response to intermittent parathyroid hormone (PTH) is both genetic and sex specific in mice

    Adams DJ et al. · Bone · 2027 Jan · PMID 42829196

  2. Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis

    Wang D et al. · Regenerative therapy · 2026 Dec · PMID 42926909

  3. Emerging therapeutic strategies for medication-related osteonecrosis of the jaw: From microenvironmental modulation to precision medicine (Review)

    Zheng XL et al. · Experimental and therapeutic medicine · 2026 Dec · PMID 42923884

  4. Response to "Interpreting bone turnover responses and treatment persistence with once-weekly teriparatide"

    Gu J et al. · Journal of orthopaedic translation · 2026 Nov · PMID 42903896

  5. Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review

    Kafa HS et al. · Basic & clinical pharmacology & toxicology · 2026 Nov · PMID 42825520

  6. Parathyroid hormone reprograms M1/M2 macrophage fate to regulate alveolar bone remodeling during orthodontic tooth movement

    Ying Z et al. · Tissue & cell · 2026 Nov · PMID 42341432

  7. Teriparatide Topical Delivery Supports Osseointegration in Ovariectomized Rats Receiving Cafeteria Diet and Bisphosphonate: An In Vivo Experimental Study

    da Silva ACE et al. · Clinical oral implants research · 2026 Oct 26 · PMID 42931806

  8. Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults

    Lewis L et al. · The Annals of pharmacotherapy · 2026 Oct 23 · PMID 42924498

Live feed from PubMed (NCBI) for “Teriparatide (PTH 1-34)”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

198 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Teriparatide (PTH 1-34)”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
  2. [2]Neer et al., 2001 — N Engl J Med 344:1434–1441

FAQ

  • The designation refers to amino acids 1 through 34 of the 84-residue parathyroid hormone. This N-terminal fragment contains the residues needed to bind and activate the PTH1 receptor, so it reproduces the principal skeletal and renal signalling of the full hormone.

  • Brief receptor activation favours osteoblast recruitment, survival and sclerostin suppression, while sustained activation favours RANKL-driven osteoclast formation. The timing of PTH1R signalling therefore determines whether formation or resorption dominates, a principle extensively studied in rodent and cell models.

  • Teriparatide is a parathyroid hormone analogue and an osteoanabolic agent. It is an approved prescription medicine for osteoporosis in people at high fracture risk. It contrasts with antiresorptive agents, such as bisphosphonates, which act mainly by reducing osteoclast activity.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp